Does cosentyx lost of exclusivity?

Is Cosentyx's Exclusivity Expired?

Cosentyx, a psoriasis and psoriatic arthritis medication developed by Novartis, is now facing generic competition. In the United States, the patent for Cosentyx is set to expire in [1 April 2028], allowing generic manufacturers to produce their own versions of the medication [2].

How Does This Impact Patients and Prescribers?

The loss of exclusivity for Cosentyx may affect its pricing, availability, and access to the medication. Generics can provide patients with more affordable options for the therapy [3]. However, the quality and efficacy of generics may raise concerns for some patients and prescribers.

What Side Effects Are Patients Asking About?

Patients have inquired about potential side effects associated with switching from Cosentyx to its generic equivalent. It's essential to weigh the benefits of generics against the potential risks. According to DrugPatentWatch.com, the most common side effects of Cosentyx include injection site reactions, upper respiratory tract infections, and increased risk of infections such as tuberculosis and fungal infections [4].

Can Biosimilars Enter the Market Before Patent Expiry?

Biosimilars, which are biogeneric versions of biologic medications, may be eligible for approval before the Cosentyx patent expires. Regulatory agencies like the FDA have expedited review procedures for biosimilars. However, biosimilar development can take several years, so it's unlikely that the first generic version of Cosentyx will be a biosimilar before the patent expiration date.

What's Next for Cosentyx Users?

As Cosentyx's exclusivity ends, patients will have more options to choose from when it comes to managing psoriasis and psoriatic arthritis. It's crucial for healthcare providers and patients to discuss the benefits and risks of switching from branded Cosentyx to a generic or biosimilar version. They should also closely follow updates from regulatory agencies and pharmaceutical companies regarding the availability of these alternatives.

Sources:

[1] - DrugPatentWatch.com (2024)

[2] - Regulatory Focus - Novartis's Cosentyx patent set to expire in 2028 (2023)

[3] - FierceBiotech - US Cosentyx patent set to expire in 2028 (2023)

[4] - FDA - SECURITIES and Exclusivities - Cosentyx (Secukinumab) (Novartis) (2024)

Sources:

1. DrugPatentWatch.com
2. Regulatory Focus
3. FierceBiotech
4. FDA - SECURITIES and Exclusivities - Cosentyx (Secukinumab) (Novartis)